Overview of Nifedicor

Quick Facts

Property	Description
Active Ingredient	Nifedipine
Form	Oral tablets/capsules (immediate and extended-release)
Pharmacological Class	Dihydropyridine Calcium Channel Blocker (CCB)
General Purpose	To reduce blood pressure and manage angina
Origin	Synthetic compound

What Type of Medicine is Nifedicor (Nifedipine)?

Nifedicor is the name for a medicinal preparation containing the synthetic active compound, Nifedipine. This substance is chemically recognized as a dihydropyridine derivative, placing it within the major group of antihypertensive agents known as Calcium Channel Blockers (CCBs). Nifedipine is a clinically recognized first-generation CCB known for its systemic vasodilatory effects.

The drug entity is a single-ingredient product whose action is primarily focused on the muscle walls of arteries, distinguishing it from other CCBs. This specific focus on peripheral vasodilation ensures a potent reduction in resistance within the circulatory system, a key mechanism in cardiovascular therapy. Its status as a prescription-only medicine underscores the requirement for medical oversight during its use.

Composition and Available Forms

The medication is available for oral administration in two distinct oral dosage forms: conventional capsules or tablets, and specialized extended-release tablets. The core composition involves Nifedipine combined with pharmaceutical excipients necessary for delivery.

The availability of different release forms is critical; for instance, the extended-release preparations are designed to provide a steady, continuous supply of Nifedipine over a prolonged period. These extended-release forms enable stable, long-term control of blood pressure and reduce the required frequency of administration. This pharmaceutical feature helps maintain a consistent therapeutic effect for patients requiring continuous management.

Primary Action and General Purpose

Nifedicor's purpose is to manage cardiovascular strain by causing the relaxation and widening of the arteries, a process known as vasodilation. This is achieved by blocking the entry of calcium into the muscle cells of the blood vessels.

The resulting dilation helps the circulatory system in two major ways. By reducing the overall resistance that the heart must pump against, the medicine assists in lowering hypertension. Simultaneously, it promotes blood flow, which is beneficial for reducing symptoms related to restricted coronary blood flow, such as those associated with angina pectoris. The general goal of this drug type is to stabilize blood pressure and improve overall oxygenation to the heart muscle.

Regulatory References

NIH Review

What side effects are possible with Nifedicor?

Possible Side Effects and Safety Information

The safety profile of Nifedicor (Nifedipine) is formally documented by regulatory authorities, with adverse reactions classified by frequency and grouped into System-Organ Classes.

Official Frequency Classification of Adverse Reactions

Adverse reactions are formally categorized based on incidence rates observed in clinical use. The most frequently documented effects, classified as Very Common, include Headache and Peripheral Edema (swelling, often in the feet or ankles). Effects classified as Common include dizziness, fatigue, flushing (reddening of the skin), constipation, and nausea. These commonly observed reactions reflect the drug's primary action as a systemic vasodilator.

Documented Systemic Safety Characteristics

Reactions are grouped into affected physiological systems. Effects often categorized under Vascular Disorders include flushing and hypotension, while Nervous System Disorders include headache and dizziness. The label also documents effects on the Gastrointestinal Disorders (e.g., constipation, gingival hyperplasia) and Cardiac Disorders (e.g., palpitations, tachycardia).

Serious adverse reactions are specifically listed and include the potential for severe Hypotension, and rare but clinically significant events such as Agranulocytosis and severe hypersensitivity reactions, including Angioedema. The label also notes that new onset, increased frequency, or increased severity of Angina Pectoris may occur, particularly at the start of treatment or following a dose increase.

Regulatory Safety Constraints

The official prescribing information identifies specific safety constraints. Nifedicor is contraindicated in conditions like cardiogenic shock, hemodynamically unstable angina, and use within the first four weeks following an acute myocardial infarction. Special consideration is advised for patients with Hepatic Impairment, potentially requiring dosage adjustments due to the drug’s metabolism.

Overdose and Emergency Response

Overdose Scope

Domain	Description (Strictly Label-Derived)
Documented Overdose Presentations	An overdose is officially documented to present with signs of severe hypotension and disturbances in heart rate, including both bradycardia and tachycardia. Severe manifestations include loss of consciousness or coma, and documented physiological findings include metabolic acidosis and hyperglycemia.
Physiological Systems Affected (as stated in label)	Primarily the cardiovascular system (blood pressure and heart rhythm) and the Central Nervous System (level of consciousness).
Dose-related or Exposure-related Factors (if applicable)	Ingestion of a toxic amount, especially of a sustained-release formulation, requires extended observation due to the potential for delayed toxicity.
Population-specific Overdose Notes (if applicable)	Increased risk of toxicity and greater severity of overdose may occur in patients with pre-existing impaired liver function (hepatic impairment).
Emergency-response statements (as written in official documents)	Management is based on immediate symptomatic and supportive treatment. Procedures such as gastric lavage or administration of activated charcoal may be considered for recent ingestion.
When immediate medical help is required (label-derived phrasing only)	Seek immediate medical attention or contact emergency services immediately upon suspected overdose. Hospital monitoring is required for all such events.

Overdose Classifications (High-Level)

Classification	Description (Strictly Regulatory)
Severity classification (as defined in official documents)	Overdose may lead to severe or life-threatening outcomes, including cardiogenic shock, cardiac arrest, pulmonary oedema, and refractory bradyarrhythmias.
Regulatory basis (EMA / FDA / etc.)	Information is derived from government-authorized prescribing information, such as the Summary of Product Characteristics (SmPC) or FDA Prescribing Information.
Overdose-context constraints (as defined in official documents)	No specific antidote is known; supportive measures include intravenous calcium salts, volume replacement, and the use of pressor agents to address circulatory instability.

Connection to the overall overdose profile:

Official regulatory documents define the Nifedipine overdose profile by detailing a high risk for acute cardiovascular collapse and listing severe manifestations such as refractory bradyarrhythmias and pulmonary oedema. These documents mandate immediate action by requiring individuals to seek immediate medical attention and undergo hospital monitoring, particularly because no specific pharmacological antidote is known and treatment is restricted to intensive symptomatic support.

Therapeutic Uses of Nifedicor

What Nifedicor Treats: Main Uses and Benefits

Nifedicor (Nifedipine) is commonly used to help provide cardiovascular support by addressing conditions that result in excessive strain on the heart and blood vessels. Its primary therapeutic roles are relevant for managing two major symptomatic domains.

Management of Chronic High Blood Pressure

The medication is commonly used to help manage the condition of essential hypertension (high blood pressure), a condition marked by increased physiological stress. It is used for managing elevated arterial pressure, a primary therapeutic goal that supports the patient during episodes of heightened discomfort related to vascular strain. By assisting in blood pressure stabilization, the medication helps maintain a sense of stability when symptoms related to systemic imbalance are more noticeable.

Relief and Control of Chest Pain (Angina)

This application focuses on managing the symptomatic domain of Angina Pectoris, which includes the symptoms related to physical discomfort. The medication is commonly used to help with both routine chronic stable angina and episodic vasospastic angina. The use of the medication may assist with the symptomatic relief and maintaining functional stability, helping to reduce the frequency and intensity of painful episodes and assists with maintaining comfort when performing routine activities.

Specialized Blood Pressure Stabilization

Nifedicor is considered relevant in specific, supervised clinical settings to manage severe manifestations of elevated blood pressure, notably including severe hypertension associated with pregnancy. This use is considered relevant in these contexts to support blood pressure stabilization and assist with managing the symptoms related to heightened physiological activity.

Quick Fact: Relief for Angina and Hypertension

Therapeutic Focus	Condition Categories
Antihypertensive	Conditions marked by increased physiological stress (HTN)
Antianginal	Conditions involving episodic or fluctuating manifestations (Angina)

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Nifedicor (Nifedipine) — Official Regulatory Information

The eligibility for Nifedicor use is strictly defined by regulatory authorities based on a patient's clinical state, age, and physiological status.

Eligibility Scope

Classification	Official Regulatory Status
Populations for whom use is allowed	Adults aged 18 years and older for approved uses.
Populations for whom use is not recommended	Pediatric Population (under 18 years): Safety and efficacy have not been established; use is not recommended.
	Pregnant and Breastfeeding women: Use is generally not recommended, as Nifedipine is excreted in human milk, and pregnancy use is restricted unless the clinical benefit clearly outweighs the risk.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Nifedipine or other related compounds.
	Patients in cardiogenic shock, with unstable angina pectoris, or during the first four weeks of an acute myocardial infarction (MI).
	Patients taking the anti-tuberculosis drug Rifampicin concomitantly (due to the risk of therapeutic failure).

Condition-Specific Eligibility

Official labeling requires specific considerations for certain patient groups:

Severe Hepatic Impairment: Requires careful monitoring, and a dose reduction may be necessary due to altered drug clearance.
Gastrointestinal Narrowing: Contraindicated for certain extended-release formulations due to the risk of obstruction.
Older Adult Patients (65 years): Conditional use; requires close monitoring as these patients may have increased sensitivity or impaired liver function.

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use Nifedicor by establishing absolute contraindications that prohibit use in specific cardiovascular emergencies and hypersensitivity cases. The profile also sets clear conditional limitations based on age and organ function, ensuring that use is restricted or closely monitored in populations where safety or efficacy data is limited or where drug clearance may be impaired.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

Nifedicor (Nifedipine) is metabolized primarily by the enzyme system CYP3A4, and its interaction profile is heavily influenced by medicines that affect the activity of this enzyme.

Interacting Agents and Constraints

Interaction Classification	Interacting Agents (Examples)	Constraint/Requirement
Contraindicated	Strong CYP3A4 Inducers (e.g., Rifampicin)	Avoid concomitant use; leads to subtherapeutic Nifedicor levels and loss of effect.
Requires Avoidance	Other Strong CYP3A4 Inducers (e.g., Phenytoin, Carbamazepine, St. John's Wort)	Avoid use due to risk of significantly reduced Nifedicor plasma concentrations.
Requires Caution/Monitoring	CYP3A4 Inhibitors (e.g., Azole Antifungals, Clarithromycin, HIV Protease Inhibitors)	Use with caution; may cause a substantial increase in Nifedicor concentrations. Close monitoring and potential dose adjustment are required.
Requires Avoidance	Grapefruit (juice/products)	Must be avoided as it inhibits CYP3A4, causing increased Nifedicor plasma concentrations.
Requires Caution/Monitoring	Other Cardiovascular Agents (e.g., Beta-Blockers, Digoxin)	Requires close monitoring for excessive blood pressure reduction or potential digitalis toxicity (with Digoxin).
Requires Caution/Monitoring	Drugs Affecting Hemostasis (e.g., Coumarin Anticoagulants, NSAIDs)	Requires close monitoring of coagulation parameters (e.g., INR) due to the increased risk of bleeding.

This structure reflects official regulatory mandates, classifying interactions based on the degree of CYP3A4 modulation and the resulting clinical requirement, from strict avoidance to careful monitoring.

Mechanism of Action

Blocking Calcium Influx in Vascular Muscle

Nifedicor acts as a targeted antagonist (blocker) of L-type Voltage-Dependent Calcium Channels ( Cav1 channels), the primary molecular target found on the walls of arteries and arterioles. The drug binds to a specific site on the channel protein, suppressing the influx of extracellular calcium ions ( Ca^2+) into the vascular smooth muscle cells. This action interrupts the excitation-contraction coupling pathway, which is the signal required to sustain muscle contraction.

Modulating Peripheral Vascular Resistance

The resulting vasodilation (widening of blood vessels) leads to a reduction in Total Peripheral Vascular Resistance (PVR) throughout the systemic circulation. By decreasing the resistance the blood encounters in the arterioles, the drug also reduces the cardiac afterload—the pressure load placed on the heart during blood ejection. This core physiological change is a mechanism by which the drug modulates systemic blood pressure.

Dosage and Administration Information

How to Use Nifedicor

Nifedicor (Nifedipine) is administered via the oral route and is available in two core forms: an Immediate-Release (IR) capsule and an Extended-Release (ER) tablet. The specific form determines the required frequency and maximum daily dose, as defined in the prescribing information.

Official Administration Schedules

Administration Type	Dosing Frequency	Starting Dose	Maximum Daily Dose
IR Capsule	Three times a day (t.i.d.)	10 mg	180 mg
ER Tablet	Once daily (q.d.)	30 mg or 60 mg	Up to 120 mg

Dosage adjustments, if required, should be implemented gradually, typically over a period of seven to fourteen days, to align with standard labeling protocols.

Mandatory Usage Constraints

For Extended-Release tablets, the medicine must be swallowed whole with a glass of water. It is a mandatory administration instruction that these tablets must not be broken, chewed, or crushed, as doing so interferes with the intended slow-release mechanism. Specific extended-release formulations may also require administration on an empty stomach.

Conversely, Immediate-Release capsules may be taken with or without food.

Special Conditions: Co-administration with grapefruit or grapefruit juice must be avoided as it affects the systemic exposure of the medicine. Furthermore, the use of IR formulations should generally be avoided in older adults, and the medicine is not recommended for pediatric use as safety and efficacy in those age groups have not been established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nifedicor

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research has widely studied Nifedicor, in the context of blood pressure management, a condition monitoring outcomes related to physiological strain or stress. The evidence base relies on extensive study designs, including many Randomized Controlled Trials (RCTs) and meta-analyses. Research examined the measurement of systolic and diastolic blood pressure (BP) changes over defined time intervals, alongside the occurrence of major Cardiovascular (CV) Events. Studies reported measured changes in both BP readings that were observed in the groups receiving extended-release formulations. However, limitations were associated with the immediate-release formulation in earlier research.

Evidence for Use in Managing Chest Pain (Angina Pectoris)

Nifedicor was evaluated in research exploring how symptoms change over time for individuals with both chronic stable angina and vasospastic angina. Study designs included specialized double-blind, placebo-controlled crossover trials and large, long-term outcome trials for comprehensive event evaluation. Research explored outcomes related to physical discomfort, including the frequency of angina episodes and objective measures like exercise capacity. Long-term outcome studies described patterns concerning the incidence of major CV Events in the study populations. The evidence landscape notes limitations associated with the immediate-release formulation, where studies described patterns associated with an increased frequency of certain acute symptoms in specific settings.

Evidence in Specialized Clinical Contexts: Severe Pregnancy-Related Hypertension

Nifedicor was studied for use in a specific, high-stakes context: the management of acute severe high blood pressure during pregnancy. Research in this area primarily involves comparative Randomized Controlled Trials (RCTs). Research examined outcomes monitoring physiological strain or stress, such as the speed and consistency of blood pressure reduction. Findings from systematic reviews indicated that evidence quality varies across studies when evaluating the findings observed with Nifedicor against other acute treatments due to methodological differences. Crucially, long-term effects are not fully established regarding perinatal outcomes in the existing research.

Research Gaps and Areas of Uncertainty

Research highlights areas where certainty remains low or where research is ongoing. For instance, data for certain groups remain insufficient, particularly for very young populations. For the pregnancy-related indications, the long-term effects are not fully established for perinatal outcomes. The research provides context but does not determine whether an individual will respond similarly to the group averages described in the studies.

Key Studies & References

Amlodipine versus Nifedipine GITS for Hypertension and Stable Angina: Primary Results of the ACTION Trial

Frequently Asked Questions (FAQ)

Common questions about Nifedicor (FAQ)

Q: How quickly does Nifedicor start to work after taking it?

A: Official prescribing information indicates that for immediate-release forms, the medicine reaches its highest level in the bloodstream within 30 to 60 minutes. Extended-release forms are specifically designed for a more gradual and sustained action over time, as determined by their formulation.

Q: How long does the effect of Nifedicor last each day?

A: The duration of the medicine’s effect is determined by the specific formulation. Immediate-release capsules require administration multiple times a day. Conversely, extended-release tablets are designed to provide a continuous therapeutic effect over a 24-hour period and are generally associated with a once-daily dosing schedule.

Q: Is Nifedicor a 'blood thinner'?

A: Nifedicor is classified as a Calcium Channel Blocker, which functions by relaxing blood vessels to help lower blood pressure. It is not classified as an anticoagulant (a blood thinner). Official drug information describes the potential for interaction with anticoagulant medicines, which may necessitate professional monitoring.

Q: Why might a doctor switch a patient from one medicine to Nifedicor?

A: Nifedicor is a specific type of medicine that powerfully relaxes the arteries, a process called vasodilation. A healthcare provider may choose it because its unique action is described as potent in relaxing the arteries, which is a key mechanism associated with reducing the overall resistance in the body's circulation.

Q: Can Nifedicor be taken by people with kidney issues?

A: Official labeling indicates that specific considerations apply to its use in patients with chronic kidney issues. Monitoring of kidney health is often advised, as rare, reversible changes in kidney function tests have been reported.

Q: What happens if I miss a dose of Nifedicor?

A: Official patient information addresses the scenario of a missed dose. Regulatory guidance typically advises patients not to compensate for a missed dose by taking more than the prescribed amount. Specific instructions for the appropriate course of action are provided in the medication guide.

Q: Is Nifedicor linked to any issues with sexual function?

A: The official adverse reaction listings include impotence as a reported side effect affecting the genito-urinary system. Any concerns regarding this or other personal health matters should be directed to a healthcare provider.

Q: Is there a generic version of Nifedicor available?

A: Yes, the active compound, Nifedipine, is available as a generic medicine. The generic version has been reviewed by regulatory bodies and is considered bioequivalent to the brand-name product.

Q: Does Nifedicor affect blood sugar levels?

A: Official regulatory monitoring guidance suggests checking blood glucose levels regularly for patients who have diabetes. This is because this class of medicine, Calcium Channel Blockers, can potentially impact insulin release and glucose metabolism. Therefore, monitoring of blood glucose levels is often recommended during treatment.

Q: Is it okay to drink alcohol in moderation while taking Nifedicor?

A: Official safety information warns that alcohol can increase the effect of Nifedicor on lowering blood pressure. This additive effect increases the risk of side effects like lightheadedness or fainting. Official documents contain warnings that caution is advised regarding alcohol consumption.

Q: Is it possible to develop a tolerance to Nifedicor over time?

A: Some clinical studies have investigated the potential for a gradual reduction in the medicine's effectiveness during continuous long-term use. This attenuation of effect, particularly in terms of its anti-anginal properties, is a topic that has been discussed in scientific literature referenced by regulatory bodies.

Q: What happens if Nifedicor is stopped suddenly?

A: Regulatory guidance indicates that any change in medication use, including cessation, should be done in consultation with a healthcare provider. Abrupt cessation of high blood pressure medication can lead to undesirable effects, including a rapid and potentially dangerous increase in blood pressure, known as rebound hypertension.

Q: What does official guidance say about Nifedicor and driving?

A: Official patient counseling information warns that Nifedicor may cause dizziness or lightheadedness, particularly when first starting treatment. Official guidance includes warnings that the medicine may impair the ability to drive or operate complex machinery.

Q: Is Nifedicor associated with changes in mood or anxiety?

A: The official listing of adverse reactions includes effects on the central nervous system. Reported effects that have been observed include nervousness, confusion, and insomnia. Specific changes to 'mood' or 'anxiety' are not universally listed in the primary categories.

Q: Why is it important to check blood pressure while on Nifedicor?

A: Checking blood pressure regularly is considered important while using Nifedicor. Official information indicates that monitoring is important to assess the medication's effectiveness in controlling hypertension and to identify the risk of excessive blood pressure reduction, which is called hypotension.

Q: Does Nifedicor treat the underlying cause of the condition?

A: Nifedicor is a management therapy that works by controlling blood vessel resistance and increasing blood flow to reduce the strain on the cardiovascular system. It is important to note that, as a management tool, it helps address symptoms and risks but does not treat the underlying, primary causes of chronic cardiovascular conditions.

Q: Can Nifedicor be prescribed for patients with diabetes?

A: Official monitoring guidelines generally indicate that Nifedicor can be used by patients with diabetes. However, regular checking of blood glucose levels is advised, as the calcium channel blocker class of medicines may have an effect on how the body handles glucose.

Q: Is Nifedicor known to interact with caffeine?

A: Caffeine is not explicitly listed in official drug interaction tables for Nifedicor. However, as a stimulant, caffeine can transiently raise blood pressure, which could potentially counteract the medicine's intended effect. Because caffeine is a stimulant, the general guidance for stimulants often includes monitoring blood pressure closely.

Q: Is Nifedicor the same kind of medicine as other 'blood pressure pills'?

A: Nifedicor is classified as a specific type of blood pressure medicine called a Dihydropyridine Calcium Channel Blocker (CCB). Unlike some other blood pressure pills, its main mechanism is focused on relaxing the blood vessels. This effect is used to reduce the overall resistance in the circulatory system.

Q: Is it normal to feel dizzy when first starting Nifedicor?

A: Yes, dizziness is listed as a common side effect of Nifedicor. Official patient counseling information specifically notes that this feeling of dizziness or lightheadedness is most likely to be observed when treatment is first started or after a dose is increased.

Q: What is the difference between Nifedicor and similar medicines ending in '-pine'?

A: Nifedicor is classified as a first-generation member of the dihydropyridine class of medicines, all of which end in '-pine' and block calcium channels. These medicines, while sharing a class, differ in their chemical structure, their speed of action, and the extent of their specific effects on the heart and blood vessels.

Q: Is Nifedicor safe to use long-term?

A: The extended-release form of Nifedicor is officially approved and supported by research for the long-term management of chronic conditions like high blood pressure and angina. However, regulatory warnings exist that generally discourage the long-term use of the immediate-release capsules for hypertension management.

Q: Are there any studies looking at Nifedicor use in older adults?

A: Regulatory information specifically addresses the use of Nifedicor in older patients (aged 65 years and older). Official documents note that this population may have increased sensitivity or difficulty clearing the drug from the body. This requires close clinical monitoring.

Q: Is Nifedicor considered a common treatment choice?

A: Nifedicor belongs to the Calcium Channel Blocker class of medicine. This is a recognized and widely used class of prescription medication that is considered a major component in the management of high blood pressure and chronic stable angina.

Q: Is there a specific time of day that Nifedicor should be taken?

A: For once-daily extended-release tablets, the design requires consistent daily administration. Official guidance describes the importance of consistent timing to ensure stable blood levels, which is critical for effective blood pressure control.

Q: Does Nifedicor help protect the heart?

A: By effectively managing high blood pressure and relieving angina, Nifedicor helps reduce the strain and workload placed on the heart. The regulatory purpose of controlling blood pressure and angina is to help reduce the risk of future cardiovascular complications associated with uncontrolled hypertension.

Q: Do food or dairy products impact the absorption of Nifedicor?

A: Immediate-release capsules can generally be taken with or without food. However, official administration instructions state that certain extended-release tablets must be taken on an empty stomach. While grapefruit must be avoided, dairy products are not typically highlighted as an interaction.

Q: Are there different strengths of Nifedicor available?

A: Yes, Nifedicor is commercially available in a variety of different strengths. This range of strengths allows healthcare providers to adjust the specific dose of the immediate-release capsules and extended-release tablets to meet the individual needs of the patient.

Q: Are there common reasons why a patient might need to stop taking Nifedicor?

A: In clinical trials, the most frequent reasons for patients to stop taking the medicine included the occurrence of side effects, especially peripheral edema (swelling) and headache. Regulatory information indicates that stopping this medicine requires consultation with a healthcare provider.

How should Nifedicor be stored and disposed of?

How to Store and Dispose of Nifedicor?

Nifedicor (nifedipine) must be stored and handled according to specific regulatory requirements to maintain its stability and effectiveness. Official labeling requires the medication to be kept in its original, tightly closed container and stored at Controlled Room Temperature (approximately 20^circC to 25^circC or 68^circF to 77^circF).

Storage Conditions

Storage Component	Requirement
Temperature	Controlled Room Temperature
Protection	Keep container tightly closed; protect from light and moisture
Child Safety	Keep out of the reach and sight of children

Disposal Instructions

If the official labeling does not include specific disposal instructions, unused Nifedicor should be mixed with an undesirable substance, such as dirt or used coffee grounds. This mixture must then be placed in a sealed plastic bag or container before being discarded with the household trash. This medicine should not be flushed down the toilet unless directed otherwise.

Nifedicor